DE60121449D1 - Behandlung von hepatitis c mit thymosin und pegyliertem interferon - Google Patents

Behandlung von hepatitis c mit thymosin und pegyliertem interferon

Info

Publication number
DE60121449D1
DE60121449D1 DE60121449T DE60121449T DE60121449D1 DE 60121449 D1 DE60121449 D1 DE 60121449D1 DE 60121449 T DE60121449 T DE 60121449T DE 60121449 T DE60121449 T DE 60121449T DE 60121449 D1 DE60121449 D1 DE 60121449D1
Authority
DE
Germany
Prior art keywords
hepatitis
pegylated interferon
thymosine
treatment
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60121449T
Other languages
English (en)
Other versions
DE60121449T2 (de
Inventor
R Rudolph
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sciclone Pharmaceuticals LLC
Original Assignee
Sciclone Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sciclone Pharmaceuticals LLC filed Critical Sciclone Pharmaceuticals LLC
Publication of DE60121449D1 publication Critical patent/DE60121449D1/de
Application granted granted Critical
Publication of DE60121449T2 publication Critical patent/DE60121449T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60121449T 2000-08-07 2001-08-06 Behandlung von hepatitis c mit thymosin und pegyliertem interferon Expired - Lifetime DE60121449T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22331200P 2000-08-07 2000-08-07
US223312P 2000-08-07
PCT/US2001/041549 WO2002011754A1 (en) 2000-08-07 2001-08-06 Treatment of hepatitis c with thymosin and pegylated interferon

Publications (2)

Publication Number Publication Date
DE60121449D1 true DE60121449D1 (de) 2006-08-24
DE60121449T2 DE60121449T2 (de) 2007-02-01

Family

ID=22835968

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60121449T Expired - Lifetime DE60121449T2 (de) 2000-08-07 2001-08-06 Behandlung von hepatitis c mit thymosin und pegyliertem interferon

Country Status (12)

Country Link
EP (1) EP1311286B1 (de)
CN (1) CN1461221A (de)
AT (1) ATE332704T1 (de)
AU (2) AU2001287160B2 (de)
CA (1) CA2418154A1 (de)
CY (1) CY1105657T1 (de)
DE (1) DE60121449T2 (de)
DK (1) DK1311286T3 (de)
ES (1) ES2267810T3 (de)
HK (1) HK1056117A1 (de)
PT (1) PT1311286E (de)
WO (1) WO2002011754A1 (de)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1072961C (zh) * 1993-03-05 2001-10-17 施塞克龙药品公司 治疗对干扰素治疗无反应者的丙型肝炎的方法
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy

Also Published As

Publication number Publication date
CN1461221A (zh) 2003-12-10
HK1056117A1 (en) 2004-02-06
EP1311286A4 (de) 2004-01-28
CY1105657T1 (el) 2010-12-22
EP1311286B1 (de) 2006-07-12
AU8716001A (en) 2002-02-18
DE60121449T2 (de) 2007-02-01
ATE332704T1 (de) 2006-08-15
EP1311286A1 (de) 2003-05-21
ES2267810T3 (es) 2007-03-16
PT1311286E (pt) 2006-11-30
DK1311286T3 (da) 2006-10-30
AU2001287160B2 (en) 2005-08-18
CA2418154A1 (en) 2002-02-14
WO2002011754A1 (en) 2002-02-14

Similar Documents

Publication Publication Date Title
ATE307608T1 (de) Kombination von doctaxel und rhumab her2 zür krebsbehandlung
AR021876A1 (es) Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado
YU77000A (sh) Primena peg-ifn-alfa i ribavirina za lečenje hroničnog hepatitisa c
DE60237721D1 (de) Kombinationstherapie mit omega-interferon zur behandlung von hepatitis c virus oder gelbfieber virus infektionen
IS8187A (is) Meðferð á fráhvarfseinkennum
MD990258A (en) Method of treatment of the acute viral hepatitis B
DE60125377D1 (de) Behandlung von hepatitis c mit thymosin, interferon und ribavirin
DE60121449D1 (de) Behandlung von hepatitis c mit thymosin und pegyliertem interferon
FI954127A0 (fi) Menetelmä C-hepatiitin hoitamiseksi interferonihoitoon reagoimattomissa potilaissa
ATE345805T1 (de) Calciumtrifluoracetat mit zytotoxischer wirkung
DK1007085T3 (da) Anvendelse af væksthormon i præparater til behandling af insulin-resistens i hjertet
EA199800770A1 (ru) Лекарственный препарат для терапевтического лечения вирусного гепатита
TR200000728T2 (tr) Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı.
KR900701311A (ko) 재조합 사람 α-인터페론을 병소내로 투여하여 편평세포 암을 치료하는 방법
TR199801801T2 (xx) Madde k�t�ye kullan�m�n�n tedavisi.
PT1150981E (pt) Composto nucleosidico terapeutico
RU2003115786A (ru) Способ лечения пневмонии у новорожденных
UA30956A (uk) Спосіб лікування алергічного риніту
EA199800820A1 (ru) Способ лечения злоупотребления лекарственными средствами

Legal Events

Date Code Title Description
8364 No opposition during term of opposition